EDIT Editas Medicine Inc.

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.

A of the presentation will be available on the “Investors” section of the Editas Medicine website at . An archived replay will be available on the website for approximately 30 days following the presentation.

About Editas Medicine

As a leading gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit .



Media and Investor Contact:
EN
06/01/2025

Underlying

EDITEditas Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Chief Financial Officer Transition

Editas Medicine Announces Chief Financial Officer Transition Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer. “We are thrilled to promote Amy to the ex...

March 20, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results an...

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneeri...

March 5, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Re...

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine m...

February 24, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Da...

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized mice Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; ...

January 13, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare C...

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. A of the presentation will be available on the “Investors” section of the Editas Medicine website at . An archived replay will be available on the website fo...

January 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch